Emergent BioSolutions (EBS) Signs $911M CDC Follow-On Contract for Anthrax Vaccine

Go back to Emergent BioSolutions (EBS) Signs $911M CDC Follow-On Contract for Anthrax Vaccine

Emergent BioSolutions to Support HHS Anthrax Preparedness Strategy With Up to $1 Billion in BioThrax Deliveries to the Strategic National Stockpile

December 8, 2016 5:13 PM EST

Company signs follow-on contract with CDC valued at up to $911 million to supply to the SNS approximately 29.4 million doses of BioThrax through September 2021BARDA issues notice of intent to separately procure approximately $100 million of BioThrax for the SNS over 24 months from contract award, which is expected in 1H 2017These actions, together with the recently awarded BARDA contract for NuThrax, reflect the U.S. governments intention to transition the stockpile of anthrax vaccines from BioThrax to NuThraxCompany re-establishes 2016 financial guidance

GAITHERSBURG, Md., Dec. 08, 2016 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc.... More